Loading...
Efficacy of subsequent docetaxel +/− ramucirumab and S‐1 after nivolumab for patients with advanced non‐small cell lung cancer
BACKGROUND: Cytotoxic chemotherapy for advanced non‐small cell lung cancer (NSCLC) as second‐line or subsequent treatment generally results in a poor treatment outcome. Several reports have indicated that subsequent cytotoxic chemotherapy in patients who have received immune checkpoint inhibitors (I...
Na minha lista:
| Udgivet i: | Thorac Cancer |
|---|---|
| Main Authors: | , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
John Wiley & Sons Australia, Ltd
2019
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6501000/ https://ncbi.nlm.nih.gov/pubmed/30913364 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.13055 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|